welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
view full news & meetings section

Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients With Familial Adenomatous Polyposis


Cancer Prevention Pharmaceuticals, Inc., a private biotech company developing novel therapeutics to prevent cancer and other diseases, and its partner Mallinckrodt Plc, a leading global specialty pharmaceutical company, today announced that CPP’s pivotal phase 3 clinical trial, CPP FAP-310, of the investigational drug CPP-1X/sulindac in patients with familial adenomatous polyposis (FAP), did not meet its primary endpoint. Specifically, the reduction of time to the first occurrence of an FAP-related event for the combination of CPP-1X (eflornithine) and sulindac (a nonsteroidal anti-inflammatory drug) did not reach statistical significance compared to the two control arms. CPP FAP-310 included only active comparator arms and was the largest and longest study ever conducted in patients with FAP.

“While we are disappointed that the CPP FAP-310 clinical trial did not achieve its primary endpoint, we are encouraged by the data that relate to important outcome measures,” said CPP CEO Jeff Jacob.

https://www.fapvoice.com/wp-content/uploads/2019/05/Cancer-Prevention-Pharmaceuticals-Logo.jpg

expertly curated content related to this topic

en English
en Englishpt Portuguesees Spanish

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close